WO2022268916A3 - Pan-coronavirus peptide vaccine - Google Patents

Pan-coronavirus peptide vaccine Download PDF

Info

Publication number
WO2022268916A3
WO2022268916A3 PCT/EP2022/067082 EP2022067082W WO2022268916A3 WO 2022268916 A3 WO2022268916 A3 WO 2022268916A3 EP 2022067082 W EP2022067082 W EP 2022067082W WO 2022268916 A3 WO2022268916 A3 WO 2022268916A3
Authority
WO
WIPO (PCT)
Prior art keywords
pan
peptide vaccine
coronavirus
coronavirus peptide
vaccine
Prior art date
Application number
PCT/EP2022/067082
Other languages
French (fr)
Other versions
WO2022268916A2 (en
Inventor
Isabelle GIRAULT
Nicolas Poirier
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of WO2022268916A2 publication Critical patent/WO2022268916A2/en
Publication of WO2022268916A3 publication Critical patent/WO2022268916A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a vaccine composition suitable for preventing or treating an infection by a coronavirus, said vaccine being adapted to provide a protection against several betacoronaviruses and optionally alphacoronaviruses.
PCT/EP2022/067082 2021-06-23 2022-06-23 Pan-coronavirus peptide vaccine WO2022268916A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305866.2 2021-06-23
EP21305866 2021-06-23

Publications (2)

Publication Number Publication Date
WO2022268916A2 WO2022268916A2 (en) 2022-12-29
WO2022268916A3 true WO2022268916A3 (en) 2023-03-02

Family

ID=77042856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/067082 WO2022268916A2 (en) 2021-06-23 2022-06-23 Pan-coronavirus peptide vaccine

Country Status (1)

Country Link
WO (1) WO2022268916A2 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
WO2015057966A2 (en) * 2013-10-16 2015-04-23 Samuel Bogoch THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
WO2021163456A1 (en) * 2020-02-14 2021-08-19 Epivax, Inc. T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
WO2021188969A2 (en) * 2020-03-20 2021-09-23 Biontech Us Inc. Coronavirus vaccines and methods of use
WO2021214081A2 (en) * 2020-04-20 2021-10-28 Nec Oncoimmunity As Sars-cov-2 vaccines
WO2021236854A1 (en) * 2020-05-19 2021-11-25 Gritstone Bio, Inc. Sars-cov-2 vaccines
WO2022011160A2 (en) * 2020-07-08 2022-01-13 The Brigham And Women's Hospital, Inc. Severe acute respiratory syndrome coronavirus 2 (sars cov-2) peptide epitopes
WO2022148455A1 (en) * 2021-01-11 2022-07-14 The Hong Kong University Of Science And Technology Identification and uses of peptide sequences of sars-cov-2 t cell and b cell epitopes
WO2022159511A2 (en) * 2021-01-19 2022-07-28 Gritstone Bio, Inc. Modified alphavirus vectors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
DE69435171D1 (en) 1993-09-14 2009-01-08 Pharmexa Inc PAN DR BINDEPROTEINS FOR INCREASING THE IMMUNE RESPONSE
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
CN1214051A (en) 1996-01-24 1999-04-14 埃皮曼尼公司 Induction of immune responese against desired determinants
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
ES2529736T3 (en) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic composition comprising a SARS coronavirus spicular protein
US8611401B2 (en) 2010-04-01 2013-12-17 Adeptence, Llc Cancellation system for millimeter-wave radar
KR101321276B1 (en) 2011-10-21 2013-10-28 삼성전기주식회사 Imaging lens
WO2012103856A2 (en) 2012-04-20 2012-08-09 华为技术有限公司 Device and method for communications correction
US9065718B2 (en) 2013-08-03 2015-06-23 Gregory Hubert Piesinger COFDM using pseudo orthogonal QPSK coding
US9259829B1 (en) 2014-08-25 2016-02-16 Cougar Holdings, Llc Roofing and nail removal hammer
US9707738B1 (en) 2016-01-14 2017-07-18 Chang Chun Petrochemical Co., Ltd. Copper foil and methods of use
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110349A2 (en) * 2003-05-14 2004-12-23 Siga Technologies, Inc. Sars t cell epitopes and methods for identifying same
WO2015057966A2 (en) * 2013-10-16 2015-04-23 Samuel Bogoch THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
WO2021163456A1 (en) * 2020-02-14 2021-08-19 Epivax, Inc. T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
WO2021188969A2 (en) * 2020-03-20 2021-09-23 Biontech Us Inc. Coronavirus vaccines and methods of use
WO2021214081A2 (en) * 2020-04-20 2021-10-28 Nec Oncoimmunity As Sars-cov-2 vaccines
WO2021236854A1 (en) * 2020-05-19 2021-11-25 Gritstone Bio, Inc. Sars-cov-2 vaccines
WO2022011160A2 (en) * 2020-07-08 2022-01-13 The Brigham And Women's Hospital, Inc. Severe acute respiratory syndrome coronavirus 2 (sars cov-2) peptide epitopes
WO2022148455A1 (en) * 2021-01-11 2022-07-14 The Hong Kong University Of Science And Technology Identification and uses of peptide sequences of sars-cov-2 t cell and b cell epitopes
WO2022159511A2 (en) * 2021-01-19 2022-07-28 Gritstone Bio, Inc. Modified alphavirus vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIJKSTRA JOHANNES M. ET AL: "Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses", vol. 10, 1 January 2021 (2021-01-01), pages 196, XP055871445, Retrieved from the Internet <URL:https://f1000research.com/articles/10-196/v1/pdf> DOI: 10.12688/f1000research.51479.1 *
JOHANNES M. DIJKSTRA: "Table 2 Identical stretches of >9 aa between SARS-CoV-2 and CCCoVs that are or may be T cell epitopes", F1000RESEARCH, 1 January 2021 (2021-01-01), Washington, DC, XP055872164, Retrieved from the Internet <URL:https://f1000researchdata.s3.amazonaws.com/linked/340787.51479-V1-1-Table_2_combined.pdf> [retrieved on 20211213], DOI: 10.1128/IAI.00866-06 *
LEE CHLOE H. ET AL: "Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains", FRONTIERS IN IMMUNOLOGY, vol. 11, 5 November 2020 (2020-11-05), XP055871433, DOI: 10.3389/fimmu.2020.579480 *
PRAKASH SWAYAM ET AL: "Genome-Wide Asymptomatic B-Cell, CD4 + and CD8 + T-Cell Epitopes, that are Highly Conserved Between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines", BIORXIV, 28 September 2020 (2020-09-28), XP055871446, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.09.27.316018v1.full.pdf> [retrieved on 20211209], DOI: 10.1101/2020.09.27.316018 *
REHMAN HAFIZ MUZZAMMEL ET AL: "A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach", vol. 9, no. 9, 18 September 2020 (2020-09-18), pages 296, XP055872020, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563440/pdf/biology-09-00296.pdf> DOI: 10.3390/biology9090296 *

Also Published As

Publication number Publication date
WO2022268916A2 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
BR112022018819A2 (en) VACCINES AGAINST CORONAVIRUS AND METHODS OF USE
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
MX2019002978A (en) Compositions comprising a non-pathogenic bacteria and methods for protecting plant and animal hosts from fungal, bacterial and viral diseases.
MX2021002719A (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
WO2022159685A3 (en) Sars-cov-2 coronavirus antibodies and uses thereof
WO2021178714A3 (en) ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
PH12021550558A1 (en) Modulators of pnpla3 expression
MX2020010697A (en) Kit, composition and combination therapy for fragile x syndrome.
MX2021009105A (en) Inactivated apxia, apxiia and apxiiia toxins.
MX2022014561A (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm.
EP3967321A4 (en) Use of cyclo-his-pro (chp) for preventing, ameliorating, or treating fibrosis
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
EP3930724A4 (en) Method and composition for inhibiting virus infection
MX2020012497A (en) Modulators of apol1 expression.
ECSP21093097A (en) MACROMOLECULAR COMPLEXES OF DITIOCARBAMATE FUNGICIDE
MX2019015007A (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides.
WO2020146700A8 (en) Lipid nanoparticles
MX2021006863A (en) Compositions comprising parabacteroides bacterial strains for treating cancer.
WO2020214220A3 (en) Cannabinoid systems and methods: water-solubility, targeting, and augmentation
EP3833387A4 (en) Compositions and methods for preventing and treating virus infection
MX2023004854A (en) Composition for treating vascular disease, composition for preventing vascular disease, composition for treating hypertension, and composition for preventing hypertension.
WO2022268916A3 (en) Pan-coronavirus peptide vaccine
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2008030260A3 (en) Treatment of variola viral infections using a tissue factor inhibitor
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22736237

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE